Form 4 for ENSC Ensysce Biosciences, Inc.
Accepted 2026-08-18 06:06:07 ET · period of report 2026-04-23 · accession 0001493152-26-038866 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-08-18 06:06 | 2026-04-23+ | ENSC | GOWER BOB G | Dir | P - Purchase | $0.4888 | +908.6K | 916.7K | +11,182% | +$444.2K |
| D | 2026-08-18 06:06 | 2026-04-23 | ENSC | GOWER BOB G | Dir | C - Cnv Deriv | — | +254.3K | 289.8K | +716% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-23 | P | A | 508,614 | $0.484 | 516,740 | D | — | — | (F1) The total of securities reported as beneficially owned reflects two reverse stock splits effected by the Issuer subsequent to the last filing on Form 4 by the Reporting Person. |
| 2 | Common | Common Stock | 2026-08-07 | P | A | 400,000 | $0.495 | 916,740 | D | — | — | |
| 3 | Derivative | Warrant | 2026-04-23 | C | A | 254,307 | — | 289,836 | D | $0.484 · 2026-04-23 to 2028-04-23 | 254,307 Common Stock | (F2) Amendment and conversion, without payment of additional consideration, of two senior convertible promissory notes, aggregate principal amount $216,000, issued in 2023 into 254,307 shares of common stock as reported in Table 1 above and a warrant to purchase 254,307 shares of common stock as reported in Table II above. In April 2026, the outstanding principal amount, together with accrued and unpaid interest, was $246,169. |